According to her trial, an online care model for psoriasis patients was just as good as traditional in-person care. “After the year 2020, there will be more people above the age of 65 than below nine years. The demand in dermatology care will outstrip the supply in future,” she said. In years to come, more and more patients with chronic skin diseases will lack regular access to dermatology providers, but teledermatology could eventually relieve the pressure of this demand.
The researches decided to assess this model in psoriasis patients because it is a chronic skin disease with a number of co-morbidities, where a team approach by a primary care practitioner (PCP) together with a dermatologist might be particularly valuable. For the study, either PCP or psoriasis patients took standardised photographs of their skin. The photos were uploaded to a connected site where dermatologists could access the images, evaluate them, and provide recommendations directly to the patient and the PCP.
The study enrolled 300 patients randomised 1:1 with online to in-person care. A change in the PASI index was the primary study outcome. Over 12 months, the difference in the average change in the PASI between the online and in-person groups was -0.271. The average change in BSA between the two groups was -0.053%. Between-group differences in PASI and BSA were within the pre-specified equivalence margins, which means that the two interventions were equivalent for this endpoint.
“It was really astonishing for us how small the difference between the groups was,” said Prof. Armstrong. In addition, the online model fared better in the PGA. As Prof. Armstrong pointed out, the online group was believed to have lower disease activity during the study compared to the in-person group and had less side effects.
“With our trial, we demonstrated that this model really works,” said Prof. Armstrong. For physicians, it will be equally important to know whether they get paid for their cooperation and whether they could be sued more. These questions will be crucial to making online care successful.
20. Armstrong, A. Abstract 6730, AAD Annual Meeting, February 16–20 2018
Posted on
Previous Article
« IL-4/IL-13 inhibition Next Article
Hyperhidrosis: Soft molecule and anticholinergic towelettes »
« IL-4/IL-13 inhibition Next Article
Hyperhidrosis: Soft molecule and anticholinergic towelettes »
Table of Contents: AAD 2018
Featured articles
Letter from The Editor
Living in the golden age of psoriasis and atopic dermatitis therapies
Late-breakers
IL-17C inhibition in AD and new oral treatments
Dual JAK/SYK inhibitor and anti-IL-33 blockade
Psoriasis: Selective IL-23 blocker, analysis of VOYAGE-2, dual IL-17 inhibitor and ustekinumab
Hyperhidrosis: Soft molecule and anticholinergic towelettes
Behcet’s syndrome and hidradenitis suppurativa
Psoriasis: an update
Oral therapeutics, supersaturation and excimer laser
Psoriasis management online?
What's hot in atopic dermatitis
AD sleep disturbance, antihistamines and osteoporosis
New topical and systematic treatments
Acne management
Winter effect and preventing scarring
Restrictive antibiotic use and novel tetracycline
Alopecia Areata
Melanoma
Melanoma incidence continues to rise in Europe
Lesions in paediatric patients and possible correlation with coffee drinking
CNNs and targeted combination therapy
Pearls of the posters
Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab
Intralesional cryosurgery and itching in psoriasis
Related Articles
December 20, 2018
Behcet’s syndrome and hidradenitis suppurativa
December 20, 2018
A glimpse into the future
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com